2010/02/22 by M. Bellido, L. Lugo, S. Castañeda +11 · 32 citations
Dentistry · Medicine · #Bone health and osteoporosis research #Bone health and treatments #Bone mineral #Calcium #Dental alveolus #Dentistry #Endocrinology #Glucocorticoid #Internal medicine #Medicine #Osteoporosis #Parathyroid Disorders and Treatments #Parathyroid hormone
paper · doi:10.1177/0022034510363082
published in Journal of Dental Research 89(4), 360-365 (SAGE Publishing)
openalex publication_date 2010/02/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/27
Intermittent parathyroid hormone (PTH) administration has been shown to be a promising therapy for systemic bone loss. Accordingly, we hypothesized that PTH could have positive results in treating oral complications of osteoporosis. Hence, we evaluated both mandibular bone loss and its response to PTH in a rabbit model of osteoporosis induced by ovariectomy and glucocorticoid administration. There was a significant and marked decrease in bone mineral density (BMD), bone mineral content (BMC), and calcium content in ash from the osteoporotic peri-alveolar region, which influenced global jaw loss. Remarkably, PTH (1-34) administration to osteoporotic rabbits almost completely reversed BMD, BMC, and calcium content fall in the peri-alveolar region, subsequently reducing global mandibular bone loss. Thus, although the peri-alveolar region is particularly susceptible to osteoporosis, it also responds well to intermittent PTH. Therefore, these results suggest that PTH might represent a valid therapy for improving the osseointegration of dental implants in persons with osteoporosis.